(5-乙基吡啶-2-基)甲胺 | 55243-14-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: (5-乙基吡啶-2-基)甲胺
• 英文名称: (5-ethylpyridin-2-yl)methanamine
• CAS: 55243-14-6
• 化学式: C₈H₁₂N₂
• mdl: MFCD09864298
• 分子量: 136.197
• InChiKey: MSBCLZATKZFKNU-UHFFFAOYSA-N

物化性质

• 沸点：
  233.5±25.0 °C(Predicted)
• 密度：
  1.005±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  (5-乙基吡啶-2-基)甲胺 生成 6-ethyl-3-oxo-2H-imidazo[1,5-a]pyridine-1-carbonyl chloride
  参考文献：
  名称：

  PALAZZO G.; PICCONI G., FARMACO. ED. SCI. , 1975, 30, NO 3, 197-207

  摘要：

  DOI：

文献信息

• [EN] SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE<br/>[FR] SULFONAMIDES EN TANT QU'INHIBITEURS DE L'ABSORPTION DE CITRATE EXTRACELLULAIRE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018104220A1

  公开（公告）日：2018-06-14

  Sulfonamides of formula (I), wherein A, R1, and R2 are as defined in the specification and the claims, can be used as medicaments for the treatment of metabolic and/or cardiovascular diseases.

  化学式（I）中的磺胺类化合物，其中A、R1和R2如规范和索赔中定义的那样，可用作治疗代谢和/或心血管疾病的药物。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Ibrahim Prabha N.

  公开号：US20090286782A1

  公开（公告）日：2009-11-19

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one of Fms protein kinase or Kit protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Fms protein kinases and/or Kit protein kinases, including rheumatoid arthritis, osteoarthritis, osteoporosis, peri-prosthetic osteolysis, systemic sclerosis, demyelinating disorders, multiple sclerosis, Charcot Marie Tooth syndrome, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, ulcerative colitis, Crohn's disease, immune thrombocytopenic purpura, myelopreparation for autologous transplantation, transplant rejection, nephritis, nephropathy, type I diabetes, acute pain, inflammatory pain, neuropathic pain, breast cancer, prostate cancer, pancreatic cancer, lung cancer, ovarian cancer, gliomas, glioblastomas, neurofibromatosis, osteolytic bone metastases, and giant cell tumors.

  描述了化合物及其盐，配方，共轭物，衍生物，形式和用途。在某些方面和实施例中，所述的化合物或其盐，配方，共轭物，衍生物，形式对Fms蛋白激酶或Kit蛋白激酶至少有一种活性。还描述了使用这些方法来治疗疾病和症状，包括与Fms蛋白激酶和/或Kit蛋白激酶活性相关的疾病和症状，包括类风湿关节炎，骨关节炎，骨质疏松症，周围假体周围骨溶解，系统性硬化症，脱髓鞘疾病，多发性硬化症，沙科特-玛丽-屈特综合症，肌萎缩侧索硬化症，阿尔茨海默病，帕金森病，溃疡性结肠炎，克罗恩病，免疫性血小板减少性紫癜，自体移植的骨髓准备，移植排斥反应，肾炎，肾病，I型糖尿病，急性疼痛，炎症性疼痛，神经病性疼痛，乳腺癌，前列腺癌，胰腺癌，肺癌，卵巢癌，神经胶质瘤，胶质母细胞瘤，神经纤维瘤病，骨转移性溶骨病和巨细胞瘤。
• Scalable Synthesis of Piperazines Enabled by Visible-Light Irradiation and Aluminum Organometallics
  作者：Samuel Suárez-Pantiga、Kilian Colas、Magnus J. Johansson、Abraham Mendoza

  DOI：10.1002/anie.201505608

  日期：2015.11.16

  The development of more active CH oxidation catalysts has inspired a rapid, scalable, and stereoselective assembly of multifunctional piperazines through a [3+3] coupling of azomethine ylides. A combination of visible‐light irradiation and aluminum organometallics is essential to promote this transformation, which introduces visible‐light photochemistry of main‐group organometallics and sets the basis

  更活性的C - H氧化催化剂的开发激发了通过偶氮甲碱叶立德的[3+3]偶联来快速、可规模化和立体选择性地组装多功能哌嗪。可见光照射和铝有机金属的结合对于促进这种转变至关重要，它引入了主族有机金属的可见光光化学，并为新型有前途的催化剂奠定了基础。
• Acetylenic Heteroaryl Compounds
  申请人：Wang Yihan

  公开号：US20130018046A1

  公开（公告）日：2013-01-17

  This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

  本发明涉及通式如下的化合物：其中变量基团如本文所定义，以及它们的制备和使用。
• 2-(ARYLOXY) ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS
  申请人：Nirschl Alexandra A.

  公开号：US20090131473A1

  公开（公告）日：2009-05-21

  The present invention relates generally to novel 2-(aryloxy)acetamides of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables W, Y, Z, R 7 , R 8 , and R 9 are as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.

  本发明涉及一般而言公式（I）的新型2-(芳氧基)乙酰胺或其立体异构体、互变异构体、药学上可接受的盐、溶剂化物或前药，其中变量W、Y、Z、R7、R8和R9如本文所定义。这些化合物是选择性抑制丝氨酸蛋白酶凝血因子VIIa的药物。